2-(2-萘氧基)乙醇 | 93-20-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-(2-萘氧基)乙醇
• 中文别名: 2-(2-羟基氧基)萘
• 英文名称: 2-(2-naphthalenyloxy)ethanol
• 英文别名: 2-(naphthalen-2-yloxy)ethanol；2-(2-naphthoxy)ethanol；2-(2-naphthyloxy)ethanol；2-(naphthalene-2-yloxy)ethanol；2-(naphthalen-2-yloxy)ethan-1-ol；2-naphthalen-2-yloxyethanol
• CAS: 93-20-9
• 化学式: C₁₂H₁₂O₂
• mdl: MFCD00016809
• 分子量: 188.226
• InChiKey: BQPBZDSDFCDSAO-UHFFFAOYSA-N

物化性质

• 熔点：
  74-76°C
• 沸点：
  355.2±15.0 °C(Predicted)
• 密度：
  1.164±0.06 g/cm3(Predicted)
• LogP：
  1.44 at 20℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn,F,Xi
• WGK Germany：
  3
• 海关编码：
  2909499000
• 危险类别：
  3
• 安全说明：
  S16,S26,S36,S37/39
• 危险类别码：
  R20/21/22,R36/37/38,R10,R36/37,R11
• 包装等级：
  III
• 危险品运输编号：
  UN 1993 3/PG 2
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  2-(2-萘氧基)乙醇 在 三乙胺 、 三氯氧磷 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Antileishmanial Ring-Substituted Ether Phospholipids

  摘要：

  Three series of ring-substituted ether phospholipids were synthesized carrying N,N,N-trimethylammonium, N-methylpiperidino, or N-methylmorpholino headgroups. The first series is substituted by 2-cyclohexyloxyethyl or 2-(4-alkylidenecyclohexyloxy)ethyl groups, the second series by cyclohexylidenealkyl or adamantylidenealkyl moieties, and the third series by 2-aryloxyethyl or 6-aryloxyhexyl groups in the alkyl portion of the molecule. The antileishmanial activity of the new compounds was evaluated in vitro against the promastigote forms of L. donovani and L. infantum using an MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide)-based microassay as a marker of cell viability. Analogues 12, 15, 24, 30, 32, 41, 43, and 45 were more potent than the control compound miltefosine (hexadecylphosphocholine) against both L. donovani and L. infantum while, derivatives 13 and 42 were equipotent to miltefosine. Analogues 16, 17, 19, 20 were more potent than miltefosine against L. infantum and compounds 27, 31, 44 were more active than miltefosine against L. donovani. Differential scanning calorimetry (DSC) was used to probe the role of individual ether phospholipids on the physicochemical properties of model membranes. The DSC scans showed that the active compounds have a more profound effect on the thermotropic properties of model membrane bilayers than the less active ones.

  DOI：

  10.1021/jm020972c
• 作为产物：
  描述：

  2-萘氧乙酸 在 氢气 作用下， 以 neat (no solvent) 为溶剂， 140.0 ℃ 、5.0 MPa 条件下， 反应 24.0h， 以86%的产率得到2-(2-萘氧基)乙醇
  参考文献：
  名称：

  TiO2负载的Re作为将羧酸加氢为醇的通用和化学选择性多相催化剂

  摘要：

  发现TiO 2负载的Re，Re / TiO 2可以促进具有芳香族和脂肪族部分的羧酸选择性氢化为相应的醇。与其他过渡金属负载的TiO 2和负载的Re催化剂相比，Re / TiO 2具有更好的效果，可用于3-苯基丙酸的选择性加氢。在温和的条件下（140℃下5 MPa H 2）以97％的产率生产3-苯丙醇。与典型的非均相催化剂相反，Re / TiO 2不会导致脱芳构化副产物的形成。该催化剂是可回收的，并且在醇的合成中显示出广泛的底物范围（22个实例；分离产率高达97％）。

  DOI：

  10.1002/chem.201604762

文献信息

• Method of treating lipidemia with aryloxyalkylaminobenzoic acids and
  申请人：American Cyanamid Company

  公开号：US04182776A1

  公开（公告）日：1980-01-08

  Aryloxyalkylaminobenzoic acids and esters as hypolipemic compounds.

  芳氧烷基氨基苯甲酸和酯作为降脂化合物。
• [EN] (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS<br/>[FR] DÉRIVÉS DE (THIO)MORPHOLINE MODULATEURS DE S1P
  申请人：ABBOTT HEALTHCARE PRODUCTS BV

  公开号：WO2011023795A1

  公开（公告）日：2011-03-03

  The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- and the linking group –Y-(CH2)n-X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO2-, -CH2-O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH2-R5, wherein R5 is -OH, -PO3H2, -OPO3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO2-; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

  本发明涉及公式（I）的（硫）吗啉衍生物，其中R1从氰基，（2-4C）炔基，（1-4C）烷基，（3-6C）环烷基，（4-6C）环烯基，（6-8C）双环烷基，（8-10C）双环基团中选择，每个基团可选择地取代为（1-4C）烷基，苯基，联苯基，萘基，每个基团可选择地取代为一个或多个取代基，独立选择自卤素，（1-4C）烷基可选择地取代为一个或多个氟原子，（2-4C）炔基，（1-4C）氧烷基可选择地取代为一个或多个氟原子，氨基，二（1-4C）烷基氨基，-SO2-（1-4C）烷基，-CO-（1-4C）烷基，-CO-O-（1-4C）烷基，-NH-CO-（1-4C）烷基和（3-6C）环烷基，苯基取代为苯氧基，苄基，苄氧基，苯乙基或单环杂环烃，每个基团可选择地取代为（1-4C）烷基，单环杂环烃可选择地取代为卤素，（1-4C）烷基或取代为苯基的苯基，可选择地取代为（1-4C）烷基，和双环杂环烃可选择地取代为（1-4C）烷基；A从-CO-O-，-O-CO-，-NH-CO-，-CO-NH，-C=C-，-CCH3-O-和连接基-Y-（CH2）n-X-中选择，其中Y连接到R1并从键，-O-，-S-，-SO-，-SO2-，-CH2-O-，-CO-，-O-CO-，-CO-O-，-CO-NH-，-NH-CO-，-C=C-和-C≡C-中选择；n是1到10的整数；X连接到苯基/吡啶基团并从键，-O-，-S-，-SO-，-SO2-，-NH，-CO-，-C=C-和-C≡C-中选择；环结构B可选择地含有一个氮原子；R2是H，（1-4C）烷基可选择地取代为一个或多个氟原子，（1-4C）氧烷基可选择地取代为一个或多个氟原子，或卤素；R3是（1-4C）烷基-R5，其中烷基基团可取代为（CH2）2形成环丙基基团或一个或两个卤素原子，或R3是（3-6C）环烷基-R5或-CO-CH2-R5，其中R5是-OH，-PO3H2，-OPO3H2，-COOH，-COO（1-4C）烷基或四唑-5-基；R4是H或（1-4C）烷基；R6是一个或多个取代基，独立选择自H，（1-4C）烷基或氧代基；W是-O-，-S-，-SO-或-SO2-；或其药学上可接受的盐，溶剂或水合物；但是，公式（I）的衍生物不是2-（4-乙基苯基）-4-吗啉乙醇或4-[4-（2-羟乙基）-2-吗啉基]苯乙腈或其药学上可接受的盐，溶剂或水合物。本发明的化合物具有对S1P受体的亲和力，可用于治疗、缓解或预防S1P受体介导的疾病和症状。
• GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS
  申请人：South Dakota Board of Regents

  公开号：US20200048305A1

  公开（公告）日：2020-02-13

  The present invention describes compositions containing cholesterol-linker-glutathione conjugates for targeting the brain by overcoming barrier entry to the CNS through the blood brain barrier (BBB), including micelle and liposome forms of such compositions. In addition, methods for treating subjects by administering such compositions are also disclosed.

  本发明描述了含有胆固醇-连接剂-谷胱甘肽共轭物的组合物，通过克服血脑屏障（BBB）进入中枢神经系统的屏障入口，包括这些组合物的胶束和脂质体形式。此外，还公开了通过给予这些组合物治疗受试者的方法。
• Omega-hydrofluoroalkyl ethers, precursor carboxylic acids and derivatives thereof, and their preparation and application
  申请人：MINNESOTA MINING AND MANUFACTURING COMPANY

  公开号：EP1170275A3

  公开（公告）日：2004-04-14

  Normally liquid, omega-hydrofluoroalkyl ether compounds (and selected mixtures thereof) have a saturated perfluoroaliphatic chain of carbon atoms interrupted by one or more ether oxygen atoms. The compounds can be prepare, e.g. by decarboxylation of the corresponding fluoroalkyl ether carboxylic acids and are useful, e.g., in cleaning and drying applications.

  通常是液体的ω-氢氟烷基醚化合物（及其选定的混合物）具有由一个或多个醚氧原子中断的饱和全氟脂肪链的碳原子。这些化合物可以通过相应的氟烷基醚羧酸的脱羧反应制备，例如在清洁和干燥应用中很有用。
• Naphthyloxyalkylaminobenzoic acids, salts and esters thereof
  申请人：American Cyanamid Company

  公开号：US04260816A1

  公开（公告）日：1981-04-07

  This disclosure describes pharmaceutical compositions having hypolipidemic and/or hypoglycemic activity which contain a substituted naphthyloxyalkylaminobenzoic acid or salt or ester thereof.

  这份披露描述了具有降脂和/或降糖活性的药物组合物，其中包含一种取代的萘氧烷基氨基苯甲酸或其盐或酯。

表征谱图